High surface IgM levels associate with shorter response to ibrutinib and BTK bypass in patients with CLL
Sign Up to like & getrecommendations! Published in 2022 at "Blood Advances"
DOI: 10.1182/bloodadvances.2021006659
Abstract: Key Points High surface IgM expression associates with shorter time to new treatment following ibrutinib therapy. Cells with high surface IgM expression retain residual signaling capacity downstream of BTK during ibrutinib therapy. read more here.
Keywords: surface igm; ibrutinib; high surface; levels associate ... See more keywords